Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc.

  • US Patent 6,737,057: Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
  • US Patent 6,129,911: Liver stem cell
  • US Patent 6,872,389: Liver stem cell
  • US Patent 6,017,760: Isolation and culture of porcine hepatocytes
  • US Patent 6,107,043: Immortalized hepatocytes
  • US Patent 5,043,260: Perfusion device with hepatocytes
  • US Patent 4,795,459: Implantable Prosthetic Device (endothelial)
  • US Patent 6,858,146: Artificial Liver Apparatus and Method (Trademarked as the SybiolR synthetic bio-liver)
  • US Patent 7,935,528 The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
US Patent 7,566,567: Immortalized hepatocytes
US20070104696A1: Use of cell lines to produce active therapeutic proteins
US20070004039A1: Immortalized hepatocytes
EP1704227B1: IMMORTALIZED HEPATOCYTES
DE602004025380C0: IMMORTALISIERTE HEPATOZYTEN
AT0456376E: IMMORTALISIERTE HEPATOZYTEN
AU8229981A1: Immortalized hepatocytes
AU4322811AH: Immortalized hepatocytes
EP1704227A4: IMMORTALIZED HEPATOCYTES
WO06041488C1: IMMORTALIZED HEPATOCYTES
WO06041488A1: IMMORTALIZED HEPATOCYTES
IL0174787A0: Use of cell lines to produce active therapeutic proteins
EP1685252A4: Use of cell lines to produce active therapeutic proteins
EP1704227A1: IMMORTALIZED HEPATOCYTES
EP1685252A2: Use of cell lines to produce active therapeutic proteins
CA2550452A1 IMMORTALIZED HEPATOCYTES
AU4322811A1 Immortalized hepatocytes
WO05034876A3 Use of cell lines to produce active therapeutic proteins
WO05034876A2 Use of cell lines to produce active therapeutic proteins
CA2541380A1 Use of cell lines to produce active therapeutic proteins
AU4280238AB Use of cell lines to produce active therapeutic proteins
AU4280238A1 Use of cell lines to produce active therapeutic proteins

Xenogenics.

When Xenogenics acquired the assets of Bioabsorbable Therapeutics, Inc., it acquired and continues to support issued U.S. patent 7,674,285: Polyanhydride polymers and their uses in biomedical devices. This process is incorporated in and trademarked as the Ideal Bio-StentR.

MultiCell ImmunoTherapeutics.

Below is a listing of the intellectual properties of which Astral, Inc. is the Assignee. This intellectual property is now owned by MultiCell Immunotherapeutics resulting from the purchase agreement between MultiCell Technologies, Inc. and Alliance Pharmaceuticals, Inc.

 

  • US20120189645A1:Compositions and methods to treat and control tumors.
  • CN100376594C: Double-chain RNA and method to initiate, enhance or adjust immunomodulatory or immune response.
  • CN1795274A: Selected RNA motifs to include cell death and/or apoptosis.
  • CN1780848A: Compositions and methods to initiate or enhance antibody and
  • major-histocompatibility class i or class ii-restricted t cell responses by
  • using immunomodulatory, non-coding RNA motifs.
  • WO04087877A3: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
  • CN1703427A: Methods and compositions to generate and control the effector profile of Tcells by simultaneous loading and activation of selected subsets of antigen presenting cells .
  • WO04087877A2: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
  • WO04027049B1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
  • WO04027049A3: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
  • WO03078595B1: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
  • WO04027049A2: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
  • WO03078595A3: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
  • CA2520181A1: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
  • CA2499066A1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
  • AU4225480A1: Selected RNA motifs to include cell death and/or apoptosis.
  • AU3276932A1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
  • WO03078595A2: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY
  • USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
  • CA2479187A1: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
  • AU3218181A1: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
  • US7566567: Immortalized hepatocytes
  • US20070104696A1: Use of cell lines to produce active therapeutic proteins
  • US20070004039A1: Immortalized hepatocytes
  • EP1704227B1:
  • IMMORTALIZED HEPATOCYTES
  • DE602004025380C0: IMMORTALISIERTE HEPATOZYTEN
  • AT0456376E: IMMORTALISIERTE HEPATOZYTEN
  • AU8229981A1: Immortalized hepatocytes
  • AU4322811AH: Immortalized hepatocytes
  • EP1704227A4: IMMORTALIZED HEPATOCYTES
  • WO06041488C1: IMMORTALIZED HEPATOCYTES
  • WO06041488A1: IMMORTALIZED HEPATOCYTES
  • IL0174787A0: Use of cell lines to produce active therapeutic proteins
  • EP1685252A4: Use of cell lines to produce active therapeutic proteins
  • EP1704227A1: IMMORTALIZED HEPATOCYTES
  • EP1685252A2: Use of cell lines to produce active therapeutic proteins
  • CA2550452A1 IMMORTALIZED HEPATOCYTES
  • AU4322811A1 Immortalized hepatocytes
  • WO05034876A3 Use of cell lines to produce active therapeutic proteins
  • WO05034876A2 Use of cell lines to produce active therapeutic proteins
  • CA2541380A1 Use of cell lines to produce active therapeutic proteins
  • AU4280238AB Use of cell lines to produce active therapeutic proteins
  • AU4280238A1 Use of cell lines to produce active therapeutic proteins